HB7091 mandates that the Department of Veterans Affairs develop an investigational research and extended-access treatment program to evaluate and, where appropriate, provide access to innovative treatments and emerging therapies for veterans with specified conditions. The Secretary must create the program within tight deadlines, designate a lead administrator, may run clinical trials and compassionate-use protocols, and report back to Congress within one year; the program is subject to review after two years.
The bill is significant because it explicitly lists psychedelic substances (e.g., psilocybin, MDMA, DMT), ketamine, ibogaine, and a catch-all for other therapies, and it directs a major federal health system to operationalize both research and patient access pathways. That combination raises immediate regulatory, clinical, and operational questions for VA clinicians, research offices, and compliance teams — from IND and controlled-substance logistics to site selection, training, and data collection — while offering a potential pathway to faster veteran access to therapies that remain investigational under federal law.
At a Glance
What It Does
The bill requires the VA to develop an investigational research program and an extended/compassionate access protocol for veterans with listed 'covered conditions,' allowing the VA to run clinical trials and consider veterans for off-trial access to specified substances and therapies. It sets a 90-day deadline to develop the program, a 60-day deadline to appoint a lead administrator, a one-year reporting requirement, and a two-year program review.
Who It Affects
Directly affects VA central research and medical operations, VA medical centers designated as trial or access sites, VA clinicians who would deliver or supervise treatments, and veterans diagnosed with PTSD, chronic pain, SUD, TBI, depression, anxiety, and other covered conditions. It also implicates contractors, suppliers of investigational products, and federal regulators (FDA, DEA) because of controlled-substance and IND issues.
Why It Matters
The bill pushes a federal health system to create structured access to therapies that are often classified as controlled or investigational, potentially accelerating real-world experience and evidence generation within the VA. That creates precedent for other federal programs and forces near-term decisions on compliance, supply, training, and liability that could reshape how veterans receive care for hard-to-treat conditions.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
HB7091 directs the Secretary of Veterans Affairs to build — on a short statutory timetable — an investigational research and extended-access treatment program for veterans who meet the bill’s definition of covered conditions (for example, PTSD, chronic pain, substance use disorders, TBI, depression, and anxiety). The VA must both design clinical trial pathways and a compassionate/extended-access protocol to consider veterans for investigational treatments when clinically appropriate.
The statute explicitly lists a set of 'innovative treatments' (including MDMA, psilocybin, DMT, ibogaine, ketamine, and related compounds) and 'emerging therapies' (including investigational drugs that meet a stated Government recovery definition and devices like deep brain stimulation or hyperbaric oxygen), while giving the Secretary authority to add other therapies or conditions.
Operationally, the bill sets clear early deadlines: the program must be developed within 90 days of enactment and a lead administrator named within 60 days. The VA may use amounts otherwise authorized to support trials, meaning the statute does not create a new dedicated appropriation but allows use of existing VA funds.
One year after enactment the Secretary must report to the Veterans’ Affairs Committees identifying host clinics, expected participant numbers, preliminary trial findings, and a cross-cutting review of safety, efficacy, costs, regulatory hurdles, and logistics for each therapy. At two years the Secretary must review the program and may extend or terminate it at their discretion.Two statutory guardrails matter for implementation: a rule of construction that the Secretary must comply with existing federal law (including investigational medical product and controlled-substance statutes), and broad Secretary discretion to designate additional treatments and covered conditions.
Those provisions mean the program is designed to operate within FDA IND/IDE pathways and DEA controls, but they also leave substantial implementation choices — from which clinics to select to how to structure informed consent, training, and security for controlled substances — to VA leadership.
The Five Things You Need to Know
The Secretary must develop the investigational research and extended-access program within 90 days of enactment and name a lead administrator within 60 days.
The VA may run clinical trials and set up a compassionate/extended-access protocol to consider veterans for access to specified substances and therapies, including MDMA, psilocybin, DMT, ibogaine, ketamine, and others the Secretary adds.
The statute does not authorize new appropriations; it allows the VA to use amounts otherwise authorized and available to support trials and access activities.
The Secretary must submit a report to congressional Veterans’ Affairs Committees within one year identifying host clinics, expected participant counts, preliminary outcomes, and an analysis of safety, cost, regulatory, and logistical considerations.
The investigational program is subject to a two-year review; after two years the Secretary may extend or terminate the program at their discretion.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
Establishes the Act’s name, 'Expanding Veterans’ Access to Emerging Treatments Act.' This is purely stylistic but signals legislative intent that the statute’s purpose is to broaden VA pathways for investigational therapies.
Sense of Congress
Lists conditions the sponsors cite as unmet needs (PTSD, chronic pain, SUD) and explicitly endorses 'psychedelic- and entactogenic-assisted therapies' as candidates for VA attention. That language frames program priorities and will influence early site and treatment selection, but it is non-binding; the operative program still depends on Section 3’s mandatory duties and the Secretary’s discretion.
Program establishment and leadership designation
Requires the Secretary to develop an 'investigational research program' within 90 days and to appoint a lead administrator within 60 days. Practically, those short timeframes force immediate internal coordination among VA research offices, medical operations, and legal/compliance teams. The provision does not specify staffing levels, budget, or whether the lead must have particular qualifications, leaving those implementation choices to VA policy.
Clinical trials and compassionate/extended access
Authorizes the VA to conduct one or more clinical trials and to develop compassionate or extended-access protocols. The VA must create processes allowing veterans to enroll in trials or be considered for off-trial access when clinically appropriate. The statute does not mandate particular study designs, enrollment criteria, or outcome measures — those operational details will determine evidentiary value and regulatory compatibility with FDA IND/expanded-access pathways.
Funding flexibility and reporting
Authorizes use of 'amounts otherwise authorized' to support trials, which gives the VA discretion to reallocate existing funds but does not guarantee new money. The one-year report must name host clinics, projected participant numbers, and include preliminary findings plus a review of safety, efficacy, cost, regulatory, and logistical considerations for each therapy. That report is a key congressional oversight tool and will shape whether the program is continued or expanded.
Sunset, definitions, and rule of construction
Requires a Secretary-led review at two years with authority to extend or terminate the program. Provides detailed statutory definitions for 'innovative treatment,' 'emerging therapies,' and 'covered condition,' listing specific substances and device categories while allowing the Secretary to add others. A rule of construction reiterates that the program must comply with existing federal laws governing investigational products and controlled substances — an explicit caveat that preserves FDA/DEA jurisdictions but leaves unresolved the operational interface between VA access and federal regulatory regimes.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Veterans with treatment-resistant PTSD, chronic pain, SUD, depression, anxiety, or TBI — the bill creates a structured path for clinical trial participation and case-by-case compassionate access to therapies that are otherwise difficult to obtain within federal systems.
- VA clinical researchers and investigators — have a clear statutory permission to run trials and generate VA-specific safety and effectiveness data on psychedelic-assisted and other novel interventions.
- Biotech and clinical trial sponsors developing psychedelic compounds and novel devices — gain a large, centralized patient cohort and a potential federal health-system partner for data generation and clinical validation.
Who Bears the Cost
- Department of Veterans Affairs — will absorb program design, oversight, training, infrastructure, and controlled-substance security costs unless Congress provides new funding; the bill explicitly allows reallocation of existing VA resources.
- VA clinicians and facility staff — must take on additional responsibilities for complex informed consent processes, specialized training in psychedelic and device protocols, controlled-substance handling, and longitudinal outcome monitoring.
- VA legal, compliance, and supply-chain teams — will face increased regulatory work to align VA actions with FDA IND/expanded-access rules and DEA controlled-substance requirements, plus potential contractual and procurement complexity for investigational products.
Key Issues
The Core Tension
The central dilemma is balancing rapid expansion of access to investigational therapies for veterans with urgent unmet needs against the need for rigorous safety oversight, regulatory compliance, and sufficient operational capacity; the bill accelerates access but leaves the hard trade-offs about evidence thresholds, funding, and controlled-substance governance to VA implementation.
The bill sets an ambitious operational timetable but leaves major implementation choices to VA leadership. The 60–90 day deadlines for appointing leadership and developing a program do not address staffing or funding needs; absent dedicated appropriations, the VA must reallocate existing resources, which could shift capacity away from other programs.
The statutory permission to use existing funds also creates internal prioritization decisions and potential legal scrutiny if resourcing undermines other statutory obligations.
A more technical tension centers on regulatory alignment. The statute instructs the VA to provide access to substances that remain investigational or are controlled under federal law, while also stating that nothing in the bill authorizes actions inconsistent with existing federal statutes.
In practice this means the VA will have to route activities through FDA IND or expanded-access mechanisms and conform to DEA scheduling requirements — an administrative and legal burden that the bill does not detail. The definitions section creates further ambiguity: phrases like 'Investigational pharmaceutical candidates that meet the Government’s Definition of Recovery' are undefined in the bill and could generate interpretive disputes over eligibility, evidence thresholds, and what treatments the Secretary may add.
Finally, clinical, safety, and logistics questions remain: how to staff and secure dosing sessions for Schedule I drugs, how to measure outcomes and adverse events consistently, and how to integrate trial or compassionate-use care into veterans’ long-term clinical records and benefits coverage.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.